Literature DB >> 26250731

Non-Hodgkin Lymphoma: Diagnosis and Treatment.

Stephen M Ansell1.   

Abstract

Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26250731     DOI: 10.1016/j.mayocp.2015.04.025

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  34 in total

1.  Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.

Authors:  Marina Weissmann; Gil Arvatz; Netanel Horowitz; Sari Feld; Inna Naroditsky; Yi Zhang; Mary Ng; Edward Hammond; Eviatar Nevo; Israel Vlodavsky; Neta Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

2.  Water-only fasting and an exclusively plant foods diet in the management of stage IIIa, low-grade follicular lymphoma.

Authors:  Alan C Goldhamer; Michael Klaper; Afsoon Foorohar; Toshia R Myers
Journal:  BMJ Case Rep       Date:  2015-12-10

3.  Impact of diffuse large B-cell lymphoma on visits to different provider specialties among elderly Medicare beneficiaries: challenges for care coordination.

Authors:  Rahul Garg; Usha Sambamoorthi; Xi Tan; Soumit K Basu; Treah Haggerty; Kimberly M Kelly
Journal:  Transl Behav Med       Date:  2018-05-23       Impact factor: 3.046

4.  Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma.

Authors:  Aishwarya Iyer; Dylan Hennessey; Sandra O'Keefe; Jordan Patterson; Weiwei Wang; Gane Ka-Shu Wong; Robert Gniadecki
Journal:  Blood Adv       Date:  2020-06-09

Review 5.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.

Authors:  An-Ping Yang; Leyna G Liu; Min-Min Chen; Fang Liu; Hua You; Lian Liu; Hua Yang; Yang Xun; Jing Liu; Rui-Xue Wang; David D Brand; Dahai Liu; Song Guo Zheng; Wen-Xing Li
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 7.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

8.  Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.

Authors:  Yuhua Feng; Jinguan Lin; Yiping Liu; Youhong Tang; Yangying Zhou; Meizuo Zhong
Journal:  Int J Exp Pathol       Date:  2019-03-25       Impact factor: 1.925

9.  Assessing Cancer Treatment Information Using Medicare and Hospital Discharge Data among Women with Non-Hodgkin Lymphoma in a Los Angeles County Case-Control Study.

Authors:  Charlie Zhong; Petra Seibold; Chun R Chao; Wendy Cozen; Joo Y Song; Dennis Weisenburger; Leslie Bernstein; Sophia S Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-17       Impact factor: 4.254

10.  Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Authors:  Paola Circosta; Angela Rita Elia; Indira Landra; Rodolfo Machiorlatti; Maria Todaro; Sabrina Aliberti; Davide Brusa; Silvia Deaglio; Sabina Chiaretti; Riccardo Bruna; Daniela Gottardi; Massimo Massaia; Filomena Di Giacomo; Anna Rita Guarini; Robin Foà; Peter W Kyriakides; Rohan Bareja; Olivier Elemento; Gurunadh R Chichili; Emanuele Monteleone; Paul A Moore; Syd Johnson; Ezio Bonvini; Alessandro Cignetti; Giorgio Inghirami
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.